<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373398</url>
  </required_header>
  <id_info>
    <org_study_id>HD901_01</org_study_id>
    <nct_id>NCT01373398</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)</brief_title>
  <official_title>Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetics of Intravesical Instillation of EO9 in Patients With Non-muscle Invasive Bladder Cancer(NMIBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Handok Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Handok Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of intravesical
      instillation of EO9 in patients with non-muscle invasive bladder cancer (NMIBC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment based on all Adverse events(causal relationship, incidence, severity, etc.)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics assessment of EO9 and it's metabolites in blood and urine</measure>
    <time_frame>before, 30, 55, 90 mins of EO9 instillation</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EO9(Apaziquone)</intervention_name>
    <description>immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are clinically diagnosed as having stage Ta, T1, histological grade G1,
             G2 urothelial carcinoma of the bladder

          -  Patients who are confirmed to be urinary cytology negative (class I, class II) within
             4 weeks prior to the present TURBT.

          -  P.S : 0-2 according to the ECOG.

        Exclusion Criteria:

          -  Patients with a primary and solitary tumor.

          -  CIS lesions in the bladder or a history thereof.

          -  Grade 3 disease or a history thereof.

          -  Patients experiencing recurrence within 3 months following TURBT for prior NMIBC.

          -  Patients having stage T1 and high-grade disease.

          -  Invasive cancer of T2 or greater, with definite lymph node or other organ metastasis,
             or a history thereof.

          -  Patients who received intravesical chemotherapy/immunotherapy treatment within 6
             months prior to the present TURBT.

          -  Patients who underwent systemic chemotherapy or radiotherapy whose field of exposure
             included the bladder.

          -  Patients with suspected bladder perforation at the time of the present TURBT.

          -  A complication of a malignant tumor of the upper urinary tract or urethra, or a
             history thereof.

          -  Malignancy within 5 years other than NMIBC (except thyroid cancer)

          -  A serious viral or bacterial infection within the last 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>EO9</keyword>
  <keyword>Apaziquone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apaziquone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

